Related Experiment Video

Updated: Aug 17, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Multiple myeloma: new aspects of biology and treatment

S Ozaki1, M Kosaka

  • 1First Department of Internal Medicine, University of Tokushima School of Medicine, Japan.

The Journal of Medical Investigation : JMI
|May 23, 1998
PubMed

Insights

Recent advances in multiple myeloma research have identified key genetic factors and cytokines like interleukin-6. New treatments including stem cell transplantation and immunotherapies aim to improve patient outcomes by overcoming drug resistance.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Multiple myeloma is characterized by genetic abnormalities (bcl-2, c-myc, ras, p53, Rb) linked to poor prognosis.
  • Cytokines such as interleukin-6 (IL-6), interleukin-1 beta, and tumor necrosis factor contribute to myeloma cell growth and bone resorption.

Purpose of the Study:

  • To review recent progress in understanding multiple myeloma biology and treatment.
  • To highlight the role of molecular genetics and cytokines in disease progression.
  • To discuss current and emerging therapeutic strategies.

Main Methods:

  • Review of recent scientific literature on multiple myeloma.
  • Analysis of molecular genetic findings and cytokine involvement.
  • Evaluation of hematopoietic stem cell transplantation and immunotherapeutic approaches.

Main Results:

  • Identification of specific genes and cytokines influencing multiple myeloma.
  • Demonstration that myeloablative chemotherapy with stem cell transplantation improves complete remission rates.
  • Recognition of drug resistance as a cause for relapse.

Conclusions:

  • Translating biological insights into clinical protocols is crucial for improving multiple myeloma treatment outcomes.
  • Targeting cell surface antigens and IL-6 signals are promising immunotherapeutic strategies.
  • Continued research into the molecular basis of multiple myeloma is essential for developing more effective therapies.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...